Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type

M. Yamamoto, T. Kuzuya, H. Baba, K. Yamada, Toshitaka Nabeshima

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.

Original languageEnglish
Pages (from-to)473-483
Number of pages11
JournalJournal of Clinical Pharmacy and Therapeutics
Volume34
Issue number4
DOIs
Publication statusPublished - 01-08-2009

Fingerprint

Vancomycin
Communicable Diseases
Pharmacokinetics
Infection
Population
Population Characteristics
Creatinine
Pneumonia
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{72984267c96f4f68abbbd84d919de801,
title = "Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type",
abstract = "Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.",
author = "M. Yamamoto and T. Kuzuya and H. Baba and K. Yamada and Toshitaka Nabeshima",
year = "2009",
month = "8",
day = "1",
doi = "10.1111/j.1365-2710.2008.01016.x",
language = "English",
volume = "34",
pages = "473--483",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "4",

}

Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. / Yamamoto, M.; Kuzuya, T.; Baba, H.; Yamada, K.; Nabeshima, Toshitaka.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 34, No. 4, 01.08.2009, p. 473-483.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type

AU - Yamamoto, M.

AU - Kuzuya, T.

AU - Baba, H.

AU - Yamada, K.

AU - Nabeshima, Toshitaka

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.

AB - Objective: To describe the population pharmacokinetics of vancomycin in patients with gram-positive infections and to investigate the influence of type of infectious disease. Methods: A two-compartment open model was adopted as a pharmacokinetic model. The nonlinear mixed-effects model was used to analyze the population pharmacokinetic models. Results: We propose one general model and one infectious disease type-specific model. The general model showed that vancomycin clearance (CL) was linearly correlated with estimated creatinine clearance (CLCR) when CLCR was less than 85 mL/min, as expressed by CL(L/h) = 0·0322 × CLCR + 0·32. The distribution volumes of the central and peripheral compartment were different in healthy volunteers and patients with gram-positive infections. The infectious disease type-specific model showed that these differences were more pronounced in patients with pneumonia. Conclusion: The population pharmacokinetic parameters of vancomycin obtained here can be used to individualize the dosage of vancomycin in institutions with similar patient population characteristics.

UR - http://www.scopus.com/inward/record.url?scp=67651253079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651253079&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2008.01016.x

DO - 10.1111/j.1365-2710.2008.01016.x

M3 - Article

C2 - 19583681

AN - SCOPUS:67651253079

VL - 34

SP - 473

EP - 483

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 4

ER -